XML 39 R26.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Goodwill and Intangible Assets (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
Summary of intangible assets by major asset class | The following sets forth the goodwill and intangible assets by major asset class:
|  |  | June 30, 2017 |  | December 31, 2016
| Useful Life (Yrs) | Gross |  | Accumulated Amortization |  | Net Book Value |  | Gross |  | Accumulated Amortization |  | Net Book Value
Non-Amortizing: |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill(a) |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |
Amortizing: |  |  |  |  |  |  |  |  |  |  |  |  |
Patents | 8 – 17 |  | 5,802,528 |  |  | (5,651,470 | ) |  | 151,058 |  |  | 5,802,528 |  |  | (5,618,854 | ) |  | 183,674 |
Licenses | 8 – 17 |  | 1,323,761 |  |  | (1,176,235 | ) |  | 147,526 |  |  | 1,323,761 |  |  | (1,161,861 | ) |  | 161,900 |
CELLECTRA®(b) | 5 – 11 |  | 8,106,270 |  |  | (7,038,569 | ) |  | 1,067,701 |  |  | 8,106,270 |  |  | (6,825,028 | ) |  | 1,281,242 |
GHRH(b) | 11 |  | 335,314 |  |  | (256,105 | ) |  | 79,209 |  |  | 335,314 |  |  | (240,264 | ) |  | 95,050 |
Bioject(c) | 2 – 15 |  | 5,100,000 |  |  | (983,889 | ) |  | 4,116,111 |  |  | 5,100,000 |  |  | (562,222 | ) |  | 4,537,778 |
Other(d) | 18 |  | 4,050,000 |  |  | (2,793,750 | ) |  | 1,256,250 |  |  | 4,050,000 |  |  | (2,681,250 | ) |  | 1,368,750 |
Total intangible assets |  |  | 24,717,873 |  |  | (17,900,018 | ) |  | 6,817,855 |  |  | 24,717,873 |  |  | (17,089,479 | ) |  | 7,628,394 |
Total goodwill and intangible assets |  |  | $ | 35,231,244 |  |  | $ | (17,900,018 | ) |  | $ | 17,331,226 |  |  | $ | 35,231,244 |  |  | $ | (17,089,479 | ) |  | $ | 18,141,765 |
(a) | Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX Pharmaceuticals in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.
(b) | CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX Pharmaceuticals.
(c) | Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.
(d) | Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 + Details
Name: | us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration